Xu Teng
Impact in
- Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
Papers in
-
- RNA modifications and cancer 11
- Epigenetics and DNA Methylation 8
- RNA Research and Splicing 7
- Cancer-related gene regulation 5
-
- Cancer-related molecular mechanisms research 7
- MicroRNA in disease regulation 4
- Co-authors
- Fangqiong Tang (5 shared papers)Dong Chen (4 shared papers)Junqi He (3 shared papers)Xinglu Huang (3 shared papers)Shi‐Mei Zhuang (5 shared papers)Hang Su (6 shared papers)Yunfei Yuan (3 shared papers)Jian‐Rong Yang (2 shared papers)
- Journals
- Frontiers in Oncology (4 papers)Carcinogenesis (3 papers)Nutrients (3 papers)Biomaterials (3 papers)Cell Death and Differentiation (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Xu Teng
57 papers receiving 4.1k citations
Xu Teng's Hit Papers
Peers
Comparison fields: 5 of 137
- Cancer Research 1.3k
- Biomaterials 859
- Molecular Biology 1.8k
- Biomedical Engineering 792
- Pharmaceutical Science 104
Countries citing papers authored by Xu Teng
This map shows the geographic impact of Xu Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Teng more than expected).
Fields of papers citing papers by Xu Teng
This network shows the impact of papers produced by Xu Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Teng. The network helps show where Xu Teng may publish in the future.
Co-authors
The 25 scholars most cited alongside Xu Teng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function Hit paper breakdown → | 2009 | 882 |
| 2 | MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity Hit paper breakdown → | 2009 | 547 |
| 3 | 2009 | 330 | |
| 4 | 2010 | 314 | |
| 5 | 2010 | 313 | |
| 6 | 2008 | 304 | |
| 7 | 2013 | 157 | |
| 8 | Micronutrient Supplementation to Reduce Cardiovascular Risk Hit paper breakdown → | 2022 | 126 |
| 9 | 2010 | 105 | |
| 10 | 2018 | 73 | |
| 11 | 2008 | 65 | |
| 12 | 2020 | 64 | |
| 13 | 2015 | 60 | |
| 14 | 2018 | 56 | |
| 15 | 2015 | 52 | |
| 16 | 2022 | 50 | |
| 17 | 2021 | 47 | |
| 18 | 2007 | 42 | |
| 19 | 2008 | 39 | |
| 20 | 2022 | 38 |
About Xu Teng
Xu Teng is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Biomedical Engineering, having authored 58 papers that have together received 4.1k indexed citations. Recurring topics across this work include RNA modifications and cancer (11 papers), Epigenetics and DNA Methylation (8 papers), RNA Research and Splicing (7 papers), Cancer-related molecular mechanisms research (7 papers), Cancer-related gene regulation (5 papers), Iron Metabolism and Disorders (4 papers), Nanoparticle-Based Drug Delivery (4 papers) and MicroRNA in disease regulation (4 papers). The work is most often cited by research in Cancer Research (1.3k citations), Biomaterials (859 citations), Molecular Biology (1.8k citations), Biomedical Engineering (792 citations) and Pharmaceutical Science (104 citations). Xu Teng has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Fangqiong Tang, Dong Chen, Junqi He, Xinglu Huang, Shi‐Mei Zhuang, Hang Su, Yunfei Yuan, Jian‐Rong Yang, Ying Zhu and Linlin Li. Their work appears in journals such as Frontiers in Oncology, Carcinogenesis, Nutrients, Biomaterials and Cell Death and Differentiation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.